Dyslipidemia and lipid management in HIV-infected patients

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 18, Issue 2, 2011, Pages 144-147

  Lo, Janet ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

cardiovascular risk factors; HIV; lipids

Indexed keywords

ANTIRETROVIRUS AGENT; ATORVASTATIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; FLUSHING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ANTI-HIV AGENTS; BIOLOGICAL MARKERS; DRUG INTERACTIONS; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HIV INFECTIONS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 79952442256     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328344556e     Document Type: Article

References (29)

1. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613-627. (Pubitemid 37100800)
2. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34. (Pubitemid 44306484)
3. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark. Ann Intern Med 2007; 146:87-95. (Pubitemid 351640011)
4. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006; 145:397-406. (Pubitemid 46768570)
5. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiencyvirus disease. J Clin Endocrinol Metab 2007; 92:2506-2512. (Pubitemid 47037350)
6. Lo J, Abbara S, Shturman L, et al. Increased prevalenceof subclinicalcoronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010; 24:243-253.
7. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-139. (Pubitemid 32150958)
8. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-1052.
9. Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37:292-298. (Pubitemid 36930361)
10. McComsey GA, O'Riordan M, Hazen SL, et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 2007; 21:921-927. (Pubitemid 46684323)
11. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-2982. (Pubitemid 37430100)
12. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100:700-705. (Pubitemid 29383638)
13. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. (Pubitemid 44837777)
14. Duprez DA, Kuller LH, Tracy R, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009; 207:524-529.
15. Hadigan C, Meigs J,Corcoran C, et al. HIV/AIDSMAJORARTICLE: metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-139; doi: 10.1086/317541. (Pubitemid 32150958)
16. Hadigan C, Mazza S, Crum D, Grinspoon S. Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients. AIDS 2007; 21:2543-2546. (Pubitemid 350145191)
17. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001. 285. 2486-2497.
18. NCEP ATP III Guidelines. http://www.nhlbi.nih.gov/guidelines/cholesterol/ atp3-rpt.htm.
19. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recentclinical trialsfor the National Cholesterol Education Program Adult Treatment Panel III guide-lines. Circulation 2004; 110:227-239. (Pubitemid 38924592)
20. Silverberg MJ, Leyden W, Hurley L, et al. Responseto newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med 2009; 150:301-313.
21. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interac-tions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16:569-577. (Pubitemid 34218852)
22. Van Luin M, Colbers A, van Ewijk-Beneken Kolmer EW, et al. Drug-drug interactions between raltegravirand pravastatin in healthy volunteers. J Acquir Immune Defic Syndr 2010; 55:82-86.
23. Aslangul E, Assoumou L, Bittar R, et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS 2010; 24:77-83.
24. Coll B, Aragones G, Parra S, et al. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 2006; 20:1675-1677. (Pubitemid 44162414)
25. Negredo E, Molto J, Puig J, et al. Ezetimibe, a promising lipid-lowering agent forthetreatment of dyslipidaemia in HIV-infected patientswith poor response to statins. AIDS 2006; 20:2159-2164. (Pubitemid 44684706)
26. Wohl DA, Waters D, Simpson RJ Jr, et al. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2008; 47:1105-1108.
27. Aberg JA, Zackin RA, Brobst SW, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005; 21:757-767. (Pubitemid 41434180)
28. Gerber JG, Kitch DW, Fichtenbaum CJ, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 2008; 47:459-466. (Pubitemid 351366958)
29. Chow DC, Stein JH, Seto TB, et al. Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy. AIDS 2010; 24:1019-1023.